Literature DB >> 12942694

Different monocyte reaction patterns in newly diagnosed, untreated rheumatoid arthritis and lupus patients probably confer disparate C-reactive protein levels.

L B Liou1.   

Abstract

OBJECTIVES: To investigate the different capacities of monocytes to produce cytokines in newly diagnosed, untreated patients with rheumatoid arthritis (RA) or systemic lupus and to examine the possible correlation among serum C-reactive protein (CRP), cytokines, swollen joint counts, and erythrocyte sedimentation rates (ESR) in untreated RA patients.
METHODS: Monocytes from untreated RA or lupus patients were cultured in vitro with lipopolysaccharide (LPS, as bacterial infection) or immune complexes (as endogenous immune deviation) and supernatants were collected for cytokine determination. Sera from RA patients were assayed for interleukin-6 (IL-6), IL-1 beta, IL-10, tumor necrosis factor-alpha (TNF-alpha) and IL-1 receptor antagonist (IL-1ra). These cytokines were related to serum CRP, swollen joint counts, and ESR.
RESULTS: RA monocytes uniformly produced IL-6, IL-1 beta, TNF-alpha, or IL-10 in vitro. In contrast, lupus monocytes could be divided into two subsets: (i) monocytes which produce cytokines on LPS stimulation but not on challenging with immune complexes; and (ii) monocytes which, interestingly, generate cytokines on stimulation by immune complexes but not LPS. These cytokines in turn stimulate the liver to synthesize CRP differently in the SLE subsets and RA patients. Moreover, serum IL-1ra levels correlated significantly with serum IL-6, IL-1 beta, and TNF-alpha concentrations (p = 0.005, 0.008, or 0.040, respectively), but not with IL-10 (p = 0.582) in RA patients.
CONCLUSIONS: Two lupus subsets exist that react either to LPS or immune complexes to produce CRP-inducing cytokines, in contrast to homogeneous RA monocytes. This is the first report that different reaction patterns of CRP-inducing cytokine production in RA and lupus monocytes probably underlie the high CRP levels in RA versus low heterogeneity in lupus. The correlation of serum IL-1ra levels with serum IL-6, IL-1 beta, or TNF-alpha concentrations, and the borderline correlation of the former with CRP levels, demonstrate that IL-1ra is an acute phase reactant in RA as well as in SLE patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12942694

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  6 in total

1.  Pregnancy outcomes in women with rheumatoid arthritis in Washington State.

Authors:  Susan D Reed; Teresa A Vollan; Megan A Svec
Journal:  Matern Child Health J       Date:  2006-07

2.  Cytokine-induced monocyte characteristics in SLE.

Authors:  Zhe Zhang; Kelly Maurer; Juan C Perin; Li Song; Kathleen E Sullivan
Journal:  J Biomed Biotechnol       Date:  2010-06-24

3.  Abnormal production of pro- and anti-inflammatory cytokines by lupus monocytes in response to apoptotic cells.

Authors:  Sangeeta Sule; Antony Rosen; Michelle Petri; Ehtisham Akhter; Felipe Andrade
Journal:  PLoS One       Date:  2011-03-14       Impact factor: 3.240

4.  Sialyltransferase and Neuraminidase Levels/Ratios and Sialic Acid Levels in Peripheral Blood B Cells Correlate with Measures of Disease Activity in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Pilot Study.

Authors:  Lieh-Bang Liou; Che-Ching Huang
Journal:  PLoS One       Date:  2016-03-16       Impact factor: 3.240

5.  Effects of betulinic acid on synovial inflammation in rats with collagen-induced arthritis.

Authors:  Jian-Ying Wang; Lei Zhang; Ying-Yi Pan; Xiao-Yun Chen; Ying Yuan
Journal:  Int J Immunopathol Pharmacol       Date:  2020 Jan-Dec       Impact factor: 3.219

6.  Blood monocyte chemotactic protein-1 (MCP-1) and adapted disease activity Score28-MCP-1: favorable indicators for rheumatoid arthritis activity.

Authors:  Lieh-bang Liou; Wen-pin Tsai; Chee J Chang; Wan-ju Chao; Meng-hsin Chen
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.